KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Aquestive Therapeutics (AQST) Net Margin (2017 - 2025)

Aquestive Therapeutics has reported Net Margin over the past 9 years, most recently at 244.79% for Q4 2025.

  • Quarterly results put Net Margin at 244.79% for Q4 2025, down 10108.0% from a year ago — trailing twelve months through Dec 2025 was 188.09% (down 11141.0% YoY), and the annual figure for FY2025 was 188.09%, down 11141.0%.
  • Net Margin for Q4 2025 was 244.79% at Aquestive Therapeutics, down from 120.61% in the prior quarter.
  • Over the last five years, Net Margin for AQST hit a ceiling of 72.46% in Q1 2023 and a floor of 618.35% in Q2 2021.
  • Median Net Margin over the past 5 years was 112.59% (2021), compared with a mean of 143.5%.
  • Biggest five-year swings in Net Margin: soared 41458bps in 2022 and later tumbled -17889bps in 2024.
  • Aquestive Therapeutics' Net Margin stood at 261.28% in 2021, then surged by 56bps to 115.63% in 2022, then surged by 47bps to 61.42% in 2023, then tumbled by -134bps to 143.72% in 2024, then crashed by -70bps to 244.79% in 2025.
  • The last three reported values for Net Margin were 244.79% (Q4 2025), 120.61% (Q3 2025), and 135.44% (Q2 2025) per Business Quant data.